SECOS cashing in as shift to bioplastics ramps up
Sustainable and eco-friendly bioplastics developer, SECOS Group Limited (ASX:SES), today provided its quarterly report and cash flow statement for the quarter ended 30 September 2018.
Sales for the quarter were up 39% on the prior year to $1.7 million, while cash flow improved by $0.5 million on the September 2017 quarter.
But the stand-out highlight came from the growth in the company’s bioplastic resin sales, which grew by 296% on year. And this is where the company is anticipating strong growth going forward. Further to this, positive feedback from prospective packaging customers in the US, Europe and Asia provides confidence in continued growth in SES’s global bioplastic resin sales.
The company commenced bioplastic resin production at its new Malaysian bioplastic plant in July this year. It has delivered initial orders to local customers and is now ramping up production to meet growing demand.
The new 30,000sq ft. facility is ideally located close to Malaysia’s largest port, and will provide the company with additional capacity and sales to meet the growing global demand for bioplastics.
Additionally, trials of SECOS’s bioplastic resin have been approved for commercial supply to major bag makers in Malaysia. This generated significant interest from other bag makers, who are keen to source locally made bioplastic resin to comply with the regulatory ban on all single use traditional plastic bags, coming into effect in Malaysia on 1 July 2019.
The company’s sales growth, particularly in bioplastic resins, is underpinned by the continuing global shift to bioplastics — an annual industry sales expected to grow by 15% and to double to $6 billion by 2023.
SES ended the quarter with $0.5 million in cash. This excludes a placement and rights issue announced on 23 October 2018 to raise up to $3.8 million before costs. A further $2 million cash will come in during November 2018 from settlement of its Malaysian land and building sale, following the repayment of $1.3 million in debt at settlement.
SES will consider further cost-saving initiatives during the year and believes further improvements are possible.
Net cash outflow from operations was $0.7 million — this is an improvement over the previous quarter while investing in the start-up of the new bioplastic resin plant in Malaysia. Operating cash outflow for the September quarter improved by $0.5 million year-on-year.
SECOS Managing Director, Stephen Walters, said: “The start of production from our new bioplastic resin plant in Malaysia was an exciting milestone for SECOS, which should enable us to meet growing demand for our resin products at improved margins. We will be ramping up production of both our Malaysia and China plants to keep pace with growing global demand.
“We are undertaking a review of our Australian subsidiary Stellar Films to identify how to best utilise the assets going forward, given our strategy to be a world leader in bioplastics.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.